Navigation Links
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Date:8/19/2007

mportant milestone for us," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We believe tezampanel has the potential to offer migraine patients an important new treatment option with a novel mechanism of action and we remain on track to announce top line results from the study during the fourth quarter of this year."

In previous clinical trials, tezampanel has been administered to more than 200 healthy adult volunteers or patients. In five Phase IIa, placebo-controlled trials using intravenous administration, tezampanel demonstrated proof of concept in multiple pain models. In one placebo and active-controlled clinical trial in patients with acute migraine, the compound achieved statistical significance in all primary and secondary endpoints traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia.

About AK Receptor Antagonists

AMPA/kainate (AK) receptors are part of the glutamate biological pathway that transmits pain signals to the brain. In addition, these receptors play a critical role in the development of central sensitization phenomena -- a key component of many pain syndromes, including migraine and persistent pain states such as chronic neuropathic pain. AK receptor antagonists selectively bind to certain AK receptors to block transmission of pain signals mediated through the activation of a subtype of glutamate receptors. Because they do not bind to opioid receptors, directly bind to serotonin receptors or constrict blood vessels, the safety profile of AK antagonists may offer important advantages over existing drugs to treat migraine and other chronic pain conditions.

About Migraine

Migraine is a painful neurological condition characterized by an intense and disabling episodic headache. According to the National Headache Foundation, an estimated 30 million people in the U.S. suffer fr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Lifesciences Corporation (NYSE: EW ), the global leader ... today reported net income for the quarter ended June 30, ... Adjusted net income on a non-GAAP basis was $124.4 ... per diluted share in the prior year period. In ... per diluted share, which included a $750 million payment ...
(Date:7/28/2015)... Corporation (NASDAQ: PMD ) today announced second quarter ... The Company also announced a quarterly dividend of $0.15 ... August 7, 2015 to be paid on August 18, ... consecutive quarterly dividend. The Company,s revenue for ... versus $7.7 million for the quarter ended June 30, ...
(Date:7/28/2015)... 2015 A German Diabetes Center clinical study ... probiotic enriches human gut microbiota and modifies gut ... study involved daily administration of Nutraceutix,s L. reuteri ... patented BIO- tract ® delivery technology that ... their way to the intestinal tract. The ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2
(Date:7/28/2015)... ... July 28, 2015 , ... A new ... for inmates who continued methadone maintenance treatment (MMT) during incarceration versus those subjected ... relapse to opiate use (1) and more likely to require hospitalization or emergency ...
(Date:7/28/2015)... ... July 28, 2015 , ... The ... Soul of Philanthropy Reframed and Exhibited,” a photographic and narrative exploration of African ... Denver’s historic Five Points neighborhood. , Denver is one of only ten cities ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Edward Buckingham and Buckingham ... Roy in July 2016. Coming to Austin from Philadelphia, Dr. Roy will be ... twelve-month long training is facilitated annually by the American Academy of Facial Plastic and ...
(Date:7/28/2015)... ... 28, 2015 , ... DuPont leaders today joined public and ... more about the impact of U.S. collaborations with local partners under the U.S. ... development as an engine of broad-based economic growth in the region. , ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... and embedded building blocks for edge devices that enable the Internet of Things ... generation Intel® Core™ i7/i5 processor to provide exceptional computing power and multitasking capabilities. ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3
... Nancy Pelosi spoke on the House floor tonight in support of historic ... legislation by a vote of 219 to 212. That bill now goes to the ... passed by a vote of 220 to 211 and goes to the Senate.  Below ... ...
... of developing high grade prostate cancer, which is more likely ... a new study published early online in Cancer , ... results suggest that because infertility may be an identifiable risk ... infertile men. Research focusing on the number of children ...
... Kaiser Permanente, ... surge facility at the 2010 Pasadena Marathon in California. , ... Pasadena, CA (Vocus) March 17, 2010 -- Kaiser Permanente ... DRASH medical surge facility at the 2010 Pasadena Marathon in California., , , , ...
... With stomach irritation preventing almost 2 out of ... discovery of several substances that may be among the ... in every cup. Their report, presented here ... Society, included the counter-intuitive finding that espresso, French roast, ...
... Phyllis Schlafly , president and founder of the conservative grassroots public policy organization Eagle Forum, made the following remarks after the public announcement that formerly pro-life Democrat ... ... , ... ...
... March 21 President Barack Obama is trying to lure anti-abortion Democrats to vote yes for the Senate health bill with ... made that clear in Youngstown Sheet & Tube Company v. Sawyer , 33 US 579 (1952). , ... ... ...
Cached Medicine News:Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 2Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 3Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 4Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 5Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 6Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 7Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 8Health News:Pelosi: 'Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans' 9Health News:Infertility increases a man's risk of prostate cancer 2Health News:DRASH Keeps Marathon Runners On Track 2Health News:DRASH Keeps Marathon Runners On Track 3Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 2Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 3Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 3Health News:Betsy McCaughey Says Anti-Abortion Democrats Should not be Hoodwinked by President's Promise of Executive Order 'Fix' 2
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws angled 45 degrees....
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with fine tips and dull finish. Insulated stop with tip gap set at 0.3 mm. Smooth handle....
Medicine Products: